NCT03778593View on ClinicalTrials.gov

FOLFIRINOX for 2nd-line Treatment of BTC

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

March 1, 2019

Study Completion Date

January 14, 2021

Conditions
Biliary Tract Cancer
Interventions
DRUG

5-Fluorouracil

D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks

DRUG

Leucovorin

D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks

DRUG

Irinotecan

D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks

DRUG

Oxaliplatin

D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks

DRUG

5% dextrose water

mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin

Trial Locations (1)

49201

Dong-A University Hospital, Busan

All Listed Sponsors
lead

Dong-A University Hospital

OTHER

NCT03778593 - FOLFIRINOX for 2nd-line Treatment of BTC | Biotech Hunter | Biotech Hunter